Novik, V.Garcia B., C.Oliva I., D.2017-11-242017-11-242017-03Revista Medica de Chile. Volume 145, Issue 3, 2017, Pages 393-3960034-9887http://dx.doi.org/10.4067/S0034-98872017000300015http://repositorio.unab.cl/xmlui/handle/ria/4731Indexación: Web of Science; Scopus; Scielo.Diabetic ketoacidosis with mild hyperglycemia is a major complication of sodium-glucose cotransporter 2 inhibitors. Although its use is not approved for patients with type 1 diabetes mellitus, the drug is often prescribed with the hope of optimizing metabolic control. We report a 20 years old female with hypo-thyroidism and type 1 diabetes consulting for vomiting and abdominal pain. The patient had used canagliflozin during the two previous months. Laboratory showed a blood glucose of 200 mg/dl, a severe metabolic acidosis (pH 7.1) and ketonemia. The patient was successfully treated in the intensive care unit.esDiabetes Mellitus, Type 1Diabetic KetoacidosisGlycosuriaHyperglycemiaCetoacidosis diabética euglicémica asociada a inhibidor de cotransportador de sodio glucosa Tipo 2 en paciente con diabetes Mellitus Tipo 1Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. Report of one case with type 1 diabetesArtículo